Literature DB >> 18329760

Age-dependent tolerance to an endogenous tumor-associated antigen.

Jennifer A McWilliams1, Richard T Sullivan1, Kimberly R Jordan1, Rachel H McMahan1, Charles B Kemmler1, Marcia McDuffie2, Jill E Slansky1.   

Abstract

Immunologic tolerance to endogenous antigens reduces antitumor responses. Gp70 is an endogenous tumor-associated antigen (TAA) of the BALB/c-derived colon carcinoma CT26. We found that expression of gp70 mRNA is detectable in tissues of mice 8 months of age and older. We showed that expression of gp70 establishes immunologic tolerance and affects antitumor immunity in a similarly age-dependent manner using gp70-deficient mice. We found that tumors grew in all gp70-sufficient mice, while approximately half of gp70-deficient mice controlled tumor growth with endogenous T-cell responses. Protection in gp70-deficient mice correlated with more robust gp70-specific CTL responses, and increased numbers and avidity of responding antigen-specific T cells after vaccination. We conclude that immunosurveillance may decline with age due to increased or de novo peripheral expression of endogenous TAAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329760      PMCID: PMC2295286          DOI: 10.1016/j.vaccine.2008.01.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

1.  Sequence analysis of peptides bound to MHC class II molecules.

Authors:  A Rudensky; P Preston-Hurlburt; S C Hong; A Barlow; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

2.  The role of envelope glycoprotein processing in murine leukemia virus infection.

Authors:  E O Freed; R Risser
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

3.  The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors.

Authors:  J C Yang; D Perry-Lalley
Journal:  J Immunother       Date:  2000 Mar-Apr       Impact factor: 4.456

4.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.

Authors:  W Chen; H Qin; B Chesebro; M A Cheever
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection.

Authors:  H Hayashi; H Matsubara; T Yokota; I Kuwabara; M Kanno; H Koseki; K Isono; T Asano; M Taniguchi
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

6.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.

Authors:  H D White; D A Roeder; W R Green
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.

Authors:  T A Colella; T N Bullock; L B Russell; D W Mullins; W W Overwijk; C J Luckey; R A Pierce; N P Restifo; V H Engelhard
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

10.  Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

Authors:  M Theobald; J Biggs; J Hernández; J Lustgarten; C Labadie; L A Sherman
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more
  21 in total

Review 1.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 2.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

3.  Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Authors:  Charles B Kemmler; Eric T Clambey; Ross M Kedl; Jill E Slansky
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

4.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

5.  Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Authors:  Jonathan D Buhrman; Kimberly R Jordan; Lance U'ren; Jonathan Sprague; Charles B Kemmler; Jill E Slansky
Journal:  Cancer Res       Date:  2012-11-16       Impact factor: 12.701

6.  Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Authors:  Elodie Belnoue; Jean-François Mayol; Susanna Carboni; Wilma Di Berardino Besson; Eloise Dupuychaffray; Annika Nelde; Stefan Stevanovic; Marie-Laure Santiago-Raber; Paul R Walker; Madiha Derouazi
Journal:  JCI Insight       Date:  2019-04-23

7.  TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.

Authors:  Kimberly R Jordan; Jonathan D Buhrman; Jonathan Sprague; Brandon L Moore; Dexiang Gao; John W Kappler; Jill E Slansky
Journal:  Cancer Immunol Immunother       Date:  2012-02-21       Impact factor: 6.968

8.  Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.

Authors:  Kimberly R Jordan; Rachel H McMahan; Charles B Kemmler; John W Kappler; Jill E Slansky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

9.  Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.

Authors:  Alexander Filatenkov; Antonia M S Müller; William Wei-Lin Tseng; Sussan Dejbakhsh-Jones; Daniel Winer; Richard Luong; Judith A Shizuru; Edgar G Engleman; Samuel Strober
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

Review 10.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses.

Authors:  Tania Løve Aaes; Peter Vandenabeele
Journal:  Cell Death Differ       Date:  2020-11-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.